ישראל - עברית - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - ticagrelor - טבליות מצופות פילם - ticagrelor 60 mg - ticagrelor

ישראל - עברית - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - ticagrelor - טבליות מצופות פילם - ticagrelor 90 mg - ticagrelor

ישראל - עברית - Ministry of Health

pfizer pharmaceuticals israel ltd - sirolimus - תמיסה (פומי) - sirolimus 1 mg/ml - sirolimus - sirolimus - rapamune is indicated for the prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving a renal transplant. it is recommended that rapamune be used initially in combination with cyclosporine microemulsion and corticosteroids for 2 to 3 months. rapamune may be continued as maintenance therapy with corticosteroids only if cyclosporine can be progressively discontinued.

ישראל - עברית - Ministry of Health

neurim pharmaceuticals (1991) ltd, israel - melatonin - טבליות בשחרור ממושך - melatonin 2 mg - melatonin - melatonin - short-term treatment for primary insomnia characterized by poor quality of sleep in patients who are aged 55 or over.

ישראל - עברית - Ministry of Health

neurim pharmaceuticals (1991) ltd, israel - melatonin - טבליות בשחרור ממושך - melatonin 2 mg - melatonin

ישראל - עברית - Ministry of Health

pfizer pharmaceuticals israel ltd - meningococcus b, multicomponent vaccine; meningococcus b, multicomponent vaccine - תרחיף להזרקה - meningococcus b, multicomponent vaccine 60 mcg; meningococcus b, multicomponent vaccine 60 mcg - meningococcus b, multicomponent vaccine

ישראל - עברית - Ministry of Health

neurim pharmaceuticals (1991) ltd, israel - melatonin - טבליות בשחרור ממושך - melatonin 1 mg - melatonin

ישראל - עברית - Ministry of Health

neurim pharmaceuticals (1991) ltd, israel - melatonin - טבליות בשחרור ממושך - melatonin 5 mg - melatonin

ישראל - עברית - Ministry of Health

tzamal bio-pharma ltd - quetiapine as fumarate - טבליות בשחרור ממושך - quetiapine as fumarate 50 mg - quetiapine - quetiapine - seroquel xr is indicated for the treatment of schizophrenia .seroquel xr is effective in preventing relapse in stable schizophrenic patients who have been maintained on seroquel xr. seroquel xr is indicated for the treatment of moderate to severe manic episodes associated with bipolar disorder.treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate.seroquel xr is indicated for the treatment of major depressive episodes in bipolar disorder. seroquel xr is indicated for preventing recurrence in bipolar disorder in patients whose manic, mixed or depressive episode has responded to quetiapine treatment as monotherapy or in combination with lithium or sodium valproate. seroquel xr is indicated for add-on treatment of major depressive episods in patients with major depressive disorder (mdd) who have had sub-optimal response to antidepressant monotherapy (see section 5.1 pharmacodynamic properties). prior to initiating treatment, clinicians should

ישראל - עברית - Ministry of Health

tzamal bio-pharma ltd - quetiapine as fumarate - טבליות בשחרור ממושך - quetiapine as fumarate 200 mg - quetiapine - quetiapine - seroquel xr is indicated for the treatment of schizophrenia .seroquel xr is effective in preventing relapse in stable schizophrenic patients who have been maintained on seroquel xr. seroquel xr is indicated for the treatment of moderate to severe manic episodes associated with bipolar disorder.treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate.seroquel xr is indicated for the treatment of major depressive episodes in bipolar disorder. seroquel xr is indicated for preventing recurrence in bipolar disorder in patients whose manic, mixed or depressive episode has responded to quetiapine treatment as monotherapy or in combination with lithium or sodium valproate. seroquel xr is indicated for add-on treatment of major depressive episods in patients with major depressive disorder (mdd) who have had sub-optimal response to antidepressant monotherapy (see section 5.1 pharmacodynamic properties). prior to initiating treatment, clinicians should